1186 SAFETY AND ANTIVIRAL ACTIVITY OF ABT-267, A NOVEL NS5A INHIBITOR, DURING 3-DAY MONOTHERAPY: FIRST STUDY IN HCV GENOTYPE-1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS
2012; Elsevier BV; Volume: 56; Linguagem: Inglês
10.1016/s0168-8278(12)61198-2
ISSN1600-0641
AutoresEric Lawitz, T. Marbury, Andrew Campbell, Emily O. Dumas, Mudra Kapoor, Edward Tam, Preethi Krishnan, Carolyn M. Setze, Wenhui Xie, Thomas Podsadecki, Barry Bernstein, Lauren Williams,
Tópico(s)Hepatitis B Virus Studies
Referência(s)